Who Generates Higher Gross Profit? Bio-Techne Corporation or Taro Pharmaceutical Industries Ltd.

Bio-Techne's Profit Soars, Taro's Declines Over a Decade

__timestampBio-Techne CorporationTaro Pharmaceutical Industries Ltd.
Wednesday, January 1, 2014251411000580006000
Thursday, January 1, 2015307277000676585000
Friday, January 1, 2016336659000778966000
Sunday, January 1, 2017374541000671251000
Monday, January 1, 2018432143000463508000
Tuesday, January 1, 2019473491000445724000
Wednesday, January 1, 2020483194000399725000
Friday, January 1, 2021632850000296656000
Saturday, January 1, 2022756496000293122000
Sunday, January 1, 2023769815000268323000
Monday, January 1, 2024769725000304979000
Loading chart...

Unleashing insights

Bio-Tech vs. Pharma: A Decade of Gross Profit Trends

In the ever-evolving landscape of the pharmaceutical and biotechnology industries, understanding financial performance is crucial. Over the past decade, Bio-Techne Corporation and Taro Pharmaceutical Industries Ltd. have showcased contrasting trajectories in gross profit generation. From 2014 to 2023, Bio-Techne's gross profit surged by over 200%, peaking in 2023 with a remarkable 770 million. In contrast, Taro Pharmaceutical's profits have seen a decline, dropping by more than 50% from their 2016 high of 780 million to just 268 million in 2023. This shift highlights Bio-Techne's strategic growth and adaptability in a competitive market, while Taro faces challenges in maintaining its earlier momentum. As we look to the future, these trends offer valuable insights into the financial health and strategic direction of these industry giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025